Literature DB >> 16485116

The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.

Ryan Williams1, Amanda F Baker, Nathan T Ihle, Ashley R Winkler, Lynn Kirkpatrick, Garth Powis.   

Abstract

BACKGROUND: The purpose of the study was to evaluate the use of phospho-Akt in mouse and human skin as a surrogate target for tumor phospho-Akt to measure the effect of antitumor inhibitors of phosphatidylinositol-3-kinase (PI-3-K)/Akt (protein kinase B) signaling.
METHOD: The expression of phosphoSer473-Akt was quantitatively assessed by Western blotting in human HT-29 colon, MCF-7 breast, A-549 non small cell lung tumor xenografts in mice, and by immunohistochemistry in mouse skin and human hair.
RESULTS: The pattern of PI-3-K isoforms in human hair keratinocytes was similar to that in tumor but mouse hair keratinocytes showed a different pattern. A high level of phospho-Akt staining was present in keratinocytes of the external root sheath of the hair and was inhibited by the PI-3-K inhibitor PX-866 administered to mice, and in human hair exposed to PX-866 in culture. The inhibition of phospho-Akt by PX-866 in mouse hair keratinocytes was greater than inhibition of phospho-Akt in HT-29 and A-549 xenografts in the same mice. Phospho-Akt in mouse hair keratinocytes was inhibited by the Akt inhibitor PX-316 to a lesser degree than in MCF-7 tumor xenografts.
CONCLUSIONS: Hair offers a way of measuring the effects of PI-3-K signaling inhibitors and, in cancer patients, may provide a readily obtainable surrogate tissue for assessing PI-3-K and phospho-Akt inhibition in tumor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16485116      PMCID: PMC1486800          DOI: 10.1007/s00280-006-0190-0

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  30 in total

Review 1.  Signaling by distinct classes of phosphoinositide 3-kinases.

Authors:  B Vanhaesebroeck; M D Waterfield
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

Review 2.  Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.

Authors:  R C Stein
Journal:  Endocr Relat Cancer       Date:  2001-09       Impact factor: 5.678

3.  Involvement of follicular stem cells in forming not only the follicle but also the epidermis.

Authors:  G Taylor; M S Lehrer; P J Jensen; T T Sun; R M Lavker
Journal:  Cell       Date:  2000-08-18       Impact factor: 41.582

4.  In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.

Authors:  Emmanuelle J Meuillet; Nathan Ihle; Amanda F Baker; Jaime M Gard; Chelsea Stamper; Ryan Williams; Amy Coon; Daruka Mahadevan; Benjamin L George; Lynn Kirkpatrick; Garth Powis
Journal:  Oncol Res       Date:  2004       Impact factor: 5.574

5.  Novel application of layered expression scanning for proteomic profiling of plucked hair follicles.

Authors:  June L Traicoff; Galina Baibakov; Greg Biesecker; Frank Richardson; Arun Ramesh; Mikhail M Galperin; Kenneth K Iwata; Vladimir Knezevic
Journal:  Dermatology       Date:  2005       Impact factor: 5.366

Review 6.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

7.  The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.

Authors:  Nathan T Ihle; Gillian Paine-Murrieta; Margareta I Berggren; Amanda Baker; Wendy R Tate; Peter Wipf; Robert T Abraham; D Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2005-09       Impact factor: 6.261

Review 8.  The EGF receptor - an essential regulator of multiple epidermal functions.

Authors:  M Jost; C Kari; U Rodeck
Journal:  Eur J Dermatol       Date:  2000 Oct-Nov       Impact factor: 3.328

9.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.

Authors:  Jeffrey A Engelman; Pasi A Jänne; Craig Mermel; Joseph Pearlberg; Toru Mukohara; Christina Fleet; Karen Cichowski; Bruce E Johnson; Lewis C Cantley
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-24       Impact factor: 11.205

Review 10.  Phosphoinositide 3-kinase inhibition in cancer treatment.

Authors:  C P Berrie
Journal:  Expert Opin Investig Drugs       Date:  2001-06       Impact factor: 6.206

View more
  11 in total

Review 1.  Inhibitors of phosphatidylinositol-3-kinase in cancer therapy.

Authors:  Nathan T Ihle; Garth Powis
Journal:  Mol Aspects Med       Date:  2010-02-20

2.  Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.

Authors:  Lisa Zimmer; Uwe Hillen; Elisabeth Livingstone; Mario E Lacouture; Klaus Busam; Richard D Carvajal; Friederike Egberts; Axel Hauschild; Mohammed Kashani-Sabet; Simone M Goldinger; Reinhard Dummer; Georgina V Long; Grant McArthur; André Scherag; Antje Sucker; Dirk Schadendorf
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

3.  Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Authors:  Timothy A Yap; Mike I Walton; Lisa-Jane K Hunter; Melanie Valenti; Alexis de Haven Brandon; Paul D Eve; Ruth Ruddle; Simon P Heaton; Alan Henley; Lisa Pickard; Gowri Vijayaraghavan; John J Caldwell; Neil T Thompson; Wynne Aherne; Florence I Raynaud; Suzanne A Eccles; Paul Workman; Ian Collins; Michelle D Garrett
Journal:  Mol Cancer Ther       Date:  2010-12-29       Impact factor: 6.261

4.  Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.

Authors:  Nathan T Ihle; Robert Lemos; David Schwartz; Junghwan Oh; Robert J Halter; Peter Wipf; Lynn Kirkpatrick; Garth Powis
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

Review 5.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

Review 6.  Development of PI3K inhibitors: lessons learned from early clinical trials.

Authors:  Jordi Rodon; Rodrigo Dienstmann; Violeta Serra; Josep Tabernero
Journal:  Nat Rev Clin Oncol       Date:  2013-02-12       Impact factor: 66.675

Review 7.  Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Authors:  Joo Ern Ang; Stan Kaye; Udai Banerji
Journal:  Curr Drug Targets       Date:  2012-11       Impact factor: 3.465

Review 8.  Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

Authors:  S J Shuttleworth; F A Silva; A R L Cecil; C D Tomassi; T J Hill; F I Raynaud; P A Clarke; P Workman
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

9.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

Review 10.  Plucked human hair shafts and biomolecular medical research.

Authors:  Kevin Schembri; Christian Scerri; Duncan Ayers
Journal:  ScientificWorldJournal       Date:  2013-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.